Sep 2026· Cancer Epidemiology, Biomarkers and Prevention· pp. OF1-OF6· 0 citations
Medicine
TL;DR
High serum sFas may be related to future risk of extrahepatic biliary tract cancer in a prospective case-control study nested in the Japan Collaborative Cohort study, highlighting the need for additional studies of this biomarker in large prospective cohorts and through integrated analysis involving other cohorts.
Abstract
Background
Soluble Fas (sFas) plays multiple roles in tumorigenesis and cancer dissemination by avoiding apoptosis via connection to Fas ligand. We assessed associations of serum sFas levels with the incidence of extrahepatic biliary tract cancer (eBTC) in a prospective case-control study nested in the Japan Collaborative Cohort study.
Methods
A baseline survey was conducted from 1988 using blood samples from 39,242 individuals (35% of 110,585). Patients diagnosed with eBTC, before the end of 1997, were regarded as cases. Odds ratios (ORs) for cancer incidence associated with sFas were estimated by conditional logistic regression.
Results
This study included 73 cases and 215 controls. Participants with high sFas showed an elevated risk of cancer (P-trend = 0.01) and the third tertile of sFas showed a higher risk compared to the first tertile (OR 3.27, 95% confidence interval [CI] 1.37-7.80). In both gallbladder and extrahepatic bile duct cancers (n = 33 and 40, respectively), high sFas was associated with elevated risk (P-trend = 0.04 and 0.02, respectively). In women and the non-elderly, subjects in the highest tertiles showed higher cancer risk. Limiting subjects to those followed for over 2 years, high sFas was related to cancer risk (P-trend = 0.02) and the third tertile showed a higher risk compared to the first (OR 3.03, 95%CI 1.14-8.07).
Conclusions
High serum sFas may be related to future risk of eBTC.
IMPACT
These findings highlight the need for additional studies of this biomarker in large prospective cohorts and through integrated analysis involving other cohorts.
Background The C-reactive protein-to-lymphocyte ratio (CLR), a novel inflammation-based biomarker, has been reported to be associated with prognosis in various cancers. However, the prognostic significance of CLR remains controversial. Therefore, we performed a meta-analysis to comprehensively evaluate the prognostic v...
Xiao-Hui Liu, Shao-Bo Zhang, Yi Liu· Frontiers in Oncology· 0 citations
A possible link between sustained tibolone use and HCC risk is suggested, warranting confirmation in larger populations and longer follow-up, ideally through well-designed prospective studies.
Ji-Min Lee, Hye Jun Kim, Sun Jae Park et al.· International Journal of Can...· 0 citations
BACKGROUND AND AIM
Primary biliary cholangitis (PBC) is associated with several extrahepatic autoimmune diseases (EHAIDs), but reliable prevalence estimates are scarce. We determined the occurrence of EHAIDs in a nationwide population with PBC and their association with outcome.
METHODS
The retrospective Dutch PBC Co...
Gemma H. X. Weijsters, E. Werner, Tiki Blom et al.· Clinical Gastroenterology an...· 0 citations
Objective Caspase-8 (CASP8) is essential for apoptotic clearance of transformed cells and is encoded by the CASP8 gene. The CASP8 -652 6N del polymorphism (rs3834129) has been studied in relation to colorectal cancer (CRC) risk with conflicting outcomes. This meta-analysis aims to provide a consolidated assessment of t...
Jun Wang, C. Ye· Medeniyet Medical Journal· 0 citations
There is no data from India regarding the prevalence of Claudin 18.2 (CLDN18.2) in patients with gastric adenocarcinomas (GC).
Records of treatment-naive, histologically confirmed gastric cancer (GC) diagnosed between January 2018 and October 2023 were retrieved from a prospectively maintained database at th...
Jaspreet Kaur, Gauri Wagh, R. Patil et al.· South Asian Journal of Cance...· 0 citations
It is concluded that high levels of free T3, and a high free T3/T4 ratio were associated with a lower risk of all‐cause mortality and may be a marker of a favourable prognosis.
Annie Brange, Ylva Heyman, Kamil Demircan et al.· Cancer Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.